Table 6

Results of nominal group proceedings with percentage for acceptance (see online supplement for expanded voting tables)

InstrumentCTD-ILD
PULM+RHEUM+patients with CTD-ILD
IPF
PULM+patient with IPF
Dyspnoea
 MRC Chronic Dyspnea Scale7/9+9/12+2/3=75%10/11+1/1=92%
 Dyspnea 128/10+11/12+3/3=88%6/9+1/1=70%
 UCSD-SBQN/A7/9+1/1=80%
Cough
 Leicester cough monitor7/10+10/12+2/2=79%8/10+1/1=82%
HRQoL
 Short Form 3610/10+11/11+3/3=100%8/10+1/1=82%
 SGRQ9/10+9/11+2/2=87%8/10+1/1=82%
 VAS-PtGA10/10+11/12+2/2=96%N/A
Lung imaging
 Overall extent of ILD on HRCT11/11+9/11+3/3=92%10/10+1/1=100%
Lung physiology
 Forced vital capacity10/10+11/11+3/3=100%10/10+1/1=100%
 Diffusion capacity of lung10/10+8/10+3/3=91%10/10+1/1=100%
Survival
 All-cause mortalityUnanimous agreementUnanimous agreement
  • CTD-ILD, connective tissue disease associated interstitial lung disease; HRCT, high-resolution CT; HRQoL, health-related quality of life; IPF, idiopathic pulmonary fibrosis; MRC, Medical Research Council; PtGA, Patient Global Assessment; PULM, pulmonary specialist; RHEUM, rheumatology specialist; SGRQ, St George's Respiratory Questionnaire; UCSD-SBQ, University of California San Diego Shortness of Breath Questionnaire; VAS, visual analogue scale.